Basic Mysoline Information

• INN (International Nonproprietary Name): Primidone.
• Brand Names Available In United Kingdom: Mysoline (US brand noted; UK brand availability not specified), Primidone generics and other international trade names such as Primaclone, Lepimidin, Liskantin, Mylepsinum, Primidon Holsten, Sertan and Resimatil — UK‑specific listings not specified.
• ATC Code: N03AA03.
• Forms & Dosages: Tablets commonly available in 100 mg and 250 mg strengths; bottles of 100 tablets are a typical packaging example; occasional suspensions or syrups are not widely available.
• Manufacturers In United Kingdom: Bausch Health (Mysoline licence, USA), Global Pharma Tek (API supplier, India), Shandong Octagon Chemicals (API supplier, China) and Nantong Jinghua (API supplier, China); UK local manufacturers not specified.
• Registration Status In United Kingdom: FDA approval since 1954 noted for the United States; EU/UK national registrations typically occur via national or decentralised procedures but current UK registration status should be confirmed with the national regulator (not specified in the provided data).
• OTC / Rx Classification: Prescription‑only medicine (Rx); not available over the counter in major markets.

Latest Research Highlights (UK & EU, 2022–2025)

Which new findings should clinicians and patients know about primidone research in the UK and EU between 2022 and 2025?

Recent literature has revisited older antiepileptics such as primidone for niche indications, notably essential tremor, and for safety in vulnerable groups.

Systematic reviews and observational cohort reports from European centres emphasise some patients achieve tremor reduction comparable to propranolol, but there are higher rates of sedation and gait disturbance.

Cohort data also continue to show seizure‑frequency reductions when primidone is used as adjunctive therapy in partial and generalised epilepsy.

Regulatory reviews and pharmacovigilance assessments raise renewed concerns about pregnancy outcomes and cognitive effects in older patients, prompting calls for registry data rather than broad guideline expansion.

Long‑term retention and withdrawal rates are key signals in recent papers, with sedation and ataxia commonly cited reasons for discontinuation.

For quick clinical scanning, the table below summarises study design elements reported in the literature or flagged as study targets; numerical outcome fields are listed as not specified when not available in the provided data.

Key data highlights to watch when reading full papers are long‑term retention, withdrawal causes and rates of sedation/ataxia.

Clinicians should cross‑reference MHRA guidance and local NHS audits for UK‑specific safety messaging and for any registry participation opportunities.

Clinical Effectiveness In The UK

How well does primidone perform in NHS practice and what do patients report?

Primidone remains an established older option in NHS secondary care where first‑line agents are unsuitable, and it is used in certain tremor presentations and some epilepsy cases.

Audit reports and clinic notes within the NHS show meaningful tremor reduction and improved seizure control in a subset of patients, balanced against tolerability issues that limit long‑term continuation.

Patient‑reported benefits commonly describe reduced tremor amplitude that enables daily tasks such as writing, using cutlery and pouring drinks.

Common tolerability complaints are daytime drowsiness, dizziness and gait disturbance, which often prompt dose reduction or switching to alternatives.

Patient‑Reported Highlights

• “My tremor is smaller so I can button shirts” — improved fine motor tasks reported by some patients.
• Daytime drowsiness commonly reported during titration periods.
• Gait unsteadiness and dizziness prompt review, particularly in older adults.

Practical NHS dosing examples used in clinics: starting at 100–125 mg at bedtime and titrating toward maintenance of 250 mg three or four times daily for adults, taking tolerability into account.

Shared decision‑making is essential; always discuss sedation risk, driving restrictions and monitoring plans with the patient and record these discussions in the medical notes.

Indications And Expanded Uses (MHRA‑Approved Vs Off‑Label)

When is primidone a licensed choice, and when is it being used off‑label in UK practice?

Primidone is historically approved for epilepsy and is commonly used off‑label for essential tremor in many countries.

FDA approval exists since 1954 for the United States, and EU/UK registrations typically occur through national procedures, so current MHRA listings should be checked for product‑specific status.

In UK secondary care and neurology clinics, common indications include tonic–clonic and partial seizures as monotherapy or adjunctive therapy, and essential tremor when propranolol is unsuitable or not tolerated.

Off‑label use is frequent for essential tremor and occasionally for refractory focal seizures when other options have failed.

Licensed Indications

Epilepsy (registration varies by country; check MHRA/NHS formulary for product‑specific licensing).

Common Off‑Label Uses

Essential tremor when first‑line agents are unsuitable; other refractory seizure subtypes as adjunctive therapy.

Document informed consent for off‑label use in NHS or private settings and record outcomes in the patient record or a registry where possible.

Composition And Brand Landscape (INN, Brands, Manufacturers)

What is in the bottle and who supplies it?

The International Nonproprietary Name is primidone and the ATC classification is N03AA03, the barbituric acid derivatives subgroup of antiepileptics.

Tablets are the common formulation with strengths usually 100 mg and 250 mg.

Mysoline is a recognised brand name (noted for the US market, Bausch Health, 250 mg tablets in bottles of 100), while generics are commonly used internationally and in the UK.

Known API suppliers and manufacturers listed in the available data include Global Pharma Tek (India), Shandong Octagon Chemicals (China), and Nantong Jinghua (China).

Always check the BNF or local NHS formulary for the currently available trade preparations and national authorisation status before ordering or dispensing.

Contraindications And Special Precautions (High‑Risk Groups)

Who should not take primidone, and who needs extra caution?

Absolute contraindications in the provided data include hypersensitivity to primidone, phenobarbital or other barbiturates, and acute intermittent porphyria.

Relative contraindications requiring caution include severe hepatic or renal impairment, respiratory depression, frailty in the elderly, pregnancy and breastfeeding.

Avoid driving until individual response is known because of drowsiness and ataxia.

Counsel strict avoidance of alcohol as it potentiates central nervous system depression with primidone.

Review contraception and pregnancy planning with women of childbearing potential because of teratogenic risk and neonatal effects noted in safety statements.

• Elderly → Start low and titrate slowly; monitor gait and cognitive effects.
• Hepatic/Renal Impairment → Reduce dose or titrate cautiously and monitor LFTs/renal function.
• Pregnancy/Breastfeeding → Specialist input required; document counselling and consider pregnancy registries.

Recommend routine monitoring for long‑term users including CBC, liver and renal function and ensure occupational safety flags are recorded where fertility/teratogenicity hazards might be relevant.

Dosage Guidelines (NHS‑Aligned Regimens And Adjustments)

How is primidone started, titrated and adjusted in NHS practice?

Adult initiation commonly uses 100–125 mg at bedtime, with titration toward maintenance doses of 250 mg three or four times daily as tolerated.

For essential tremor, gradual titration toward about 250 mg twice daily is a common pragmatic approach, tailored to benefit and side effects.

Paediatric dosing is weight‑adjusted, often starting very low (for example, around 50 mg/day divided) with careful incremental increases.

Elderly patients should begin at lower doses with slower titration because of a higher risk of sedation and ataxia.

Missed dose advice: take as soon as remembered unless it is near the next dose, and do not double up.

Overdose advice: seek immediate medical attention for severe CNS depression, ataxia or nystagmus; supportive care is standard and hemodialysis may be considered in severe cases.

Interactions Overview (Drugs, Food, MHRA Yellow Card Reports)

Which drugs and substances interact with primidone and what practical steps should be taken?

Primidone increases central nervous system depression with alcohol, benzodiazepines, opioids and sedating antihistamines and should not be combined without careful supervision.

Pharmacokinetic interactions occur via enzyme induction; co‑administration with other enzyme‑inducing antiepileptics such as carbamazepine and phenytoin can change plasma levels of primidone and other medicines.

Cross‑sensitivity with phenobarbital is reported; a history of intolerance to barbiturates is an important prescribing contraindication.

From a UK pharmacovigilance perspective, suspected interaction‑related harms should be reported to the MHRA Yellow Card scheme to support post‑marketing signal detection.

No major food interactions are listed, but counsel on alcohol avoidance and on watching for increased sedation with caffeine reduction or other lifestyle changes that alter sedative burden.

Cultural Perceptions And Patient Habits (UK Patient Forums And Pharmacy Trust)

What do UK patients ask about primidone and where do they seek advice?

UK patients often consult NHS.uk pages, patient.info and community pharmacy teams for practical information and lived experience summaries.

Community pharmacies such as Boots, LloydsPharmacy and independents are trusted sources for counselling about starting and titrating primidone and for clarifying side effects.

Cultural themes include caution about older barbiturate‑class drugs because of sedation and historic stigma, and high interest in clear advice about driving, workplace safety and family planning.

Short anonymised patient quote examples can help clinicians empathise and communicate risk and benefit succinctly.

• “Will it stop my tremor enough to write again?” — functional benefit is a common priority.
• “I felt so sleepy for the first few weeks” — patients expect sedation during titration.
• “Do I need to tell my employer?” — occupational safety and driving queries are frequent.

Electronic prescribing and the NHS app are increasingly used for repeat requests and for messaging pharmacy teams about side effects, which affects how patients report problems and request supply.

Availability And Pricing Patterns (Boots, LloydsPharmacy, Online, Regional Differences)

How easily can UK patients obtain primidone and what are the cost considerations?

Primidone is a prescription‑only medicine and community pharmacy chains dispense it on NHS and private prescriptions; generics are generally more common than branded Mysoline in UK practice.

Under NHS arrangements in England patients normally pay the standard prescription charge per item unless exempt, while Scotland, Wales and Northern Ireland typically offer free prescriptions, affecting regional out‑of‑pocket costs for non‑exempt patients.

Stock can vary by chain and region; check major pharmacies and local formularies for current availability before advising patients.

Supply‑chain notes list API sourcing from India and China in the provided data, which may influence availability or brand presentation in some markets.

In our online pharmacy, mysoline is available with a prescription, with discreet delivery to United Kingdom in 5–14 days.

Comparable Medicines And Preferences (NHS Alternatives And Pros/Cons)

What are the typical alternatives on the NHS and when might they be preferred?

For epilepsy, alternatives include phenobarbital, phenytoin, carbamazepine and valproate, with selection guided by seizure type, comorbidities and reproductive plans.

For essential tremor, propranolol and gabapentin are commonly used alternatives, with propranolol often favoured for tremor where sedation is a primary concern.

Decision prompts for prescribers include pregnancy plans, hepatic disease, polypharmacy and occupational risks such as heavy machinery operation.

Record the rationale for choosing primidone in GP letters and share with the dispensing pharmacy to support medication reviews and safety monitoring.

Faq — Common NHS Patient Questions

What are the short answers patients want to hear in clinic or at the pharmacy?

Will primidone make me sleepy?

Yes; drowsiness, dizziness and ataxia are common, especially during titration, so avoid driving until you know how you react.

Can I stop primidone suddenly?

No; abrupt discontinuation risks seizure recurrence and a supervised taper under clinician guidance is required.

Is primidone safe in pregnancy?

Primidone carries risks in pregnancy; discuss with neurology and obstetric teams and consider pregnancy registries and specialist review.

How should I store primidone?

Store at room temperature (20–25°C), protect from moisture and keep in a tightly closed container per product guidance.

Guidelines For Proper Use (Pharmacist Counselling And NHS Support)

What should pharmacists and prescribers cover at initial supply and during follow‑up?

Confirm the indication and prior therapies and explain the starting and titration schedule in clear, written terms.

Warn about sedation and driving and advise strict alcohol avoidance while using primidone.

Outline monitoring requirements including baseline and periodic CBC, liver and renal function tests, plus gait and cognition checks in older patients.

Use a stepwise counselling checklist to ensure patients understand missed dose rules, overdose symptoms and when to seek help.

For women of childbearing potential, provide contraception counselling and arrange specialist review if pregnancy is planned or suspected.

Direct patients to NHS resources and MHRA Yellow Card reporting for adverse events and ensure follow‑up appointments are arranged to review efficacy and tolerability.

Where possible, use repeat dispensing and community pharmacy services to support adherence and to monitor for drug interactions or emerging side effects.

Delivery Across United Kingdom